Syntara the science explained, page-230

Seperate Application, I'm only going by Gary's comments underlined Below..

in this interview https://www.livewiremarkets.com/wires/61584

So 12 months from now, some suggestion of efficacy in those two diseases will, I think, more than double the value of the drug to a big pharma company.

Because if I came with an indication that this drug, as well as treating myelofibrosis, also does something in migraines, that's completely irrelevant. It doesn't add to the value at all.

But if you come with a related indication in the same disease area and a plausible bit of data that shows you got there, then when we eventually sell the asset, we will get value for everything they can make in myelofibrosis, but we’ll also get the same milestones in a second disease.

You almost double the size of the value of the deal.

I’ve personally done one of these deals before, a few years ago to Boehringer.

In the negotiation, we got value for at least two indications, and that's what we're aiming to do here. So those studies are particularly important.

We've got another drug with the same mechanism in lysyl oxidase inhibition, which is relevant in the skin as well.

We've been working with Professor Fiona Wood over in Perth. She's a plastic surgeon of great repute, and the physician behind developing spray on skin, which eventually became Avita, a successful company.

Fiona came to us after we started publishing our work in lysyl oxidase and said, you know, this enzyme is really important in skin scarring and I've got very little I can use at the moment. I use laser therapy, I use repeat surgery to remove scar tissue, to try and get it to heal better, and we use silicone sheeting and pressure bandages.

There's almost no pharmacological treatments in the market or in development for reducing scarring. If you go to your local pharmacy, you'll find bottles of 100 % silicone, that you have to rub into the scar regularly. And none of these things are particularly effective.

We've already done one study for three months with a cream, and we can show a 30% collagen reduction in three months compared to placebo.

So we know, I know, that this drug works in skin scarring.

And I know that skin scarring is a huge commercial opportunity. It's a different set of companies, companies with aesthetics divisions, people that sell Botox.

I'm talking to plastic surgeons in America, Europe, Japan, across Asia. In Asia keloid scarring is becoming a huge market.

This is very different from hematology in blood cancers. But I think if we can get the right clinical study, we've got a couple ongoing, which are run by Professor Wood over in Perth.

We're also thinking about what else we could do to really efficiently find a proof of concept that we can reduce scarring.

Because then we've got a huge asset on our hands and it may be something, to your earlier point, that’s run separately from the oncology program, right? If you've got proof of concept, you could even spin it into a second company jointly owned by Syntara shareholders with a dedicated team of its own..

So that's really quite exciting. It's at an early stage and we haven't spent much money on it.

We're thinking carefully about what step we might make.

We'll probably make some announcements in the first half of next year about what we're going to do next ......